Pure Biologics

Pure Biologics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Pure Biologics (PUR.WA) as of Nov 12, 2026 is -6.33 M PLN. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -12.07 M PLN — a change of -47.57% (higher).

EBITDA

-6.33 MPLN

YoY

-47.57%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Pure Biologics is 2025 -6.33 M PLN. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Pure Biologics was 2024 -12.07 M PLN. It decreases by -47.57% higher compared to the previous year.

The Pure Biologics EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-420,318.80 PLN
Jan 1, 2019
-3.63 M PLN
Jan 1, 2020
-11.56 M PLN
Jan 1, 2021
-7.56 M PLN
Jan 1, 2022
-22.13 M PLN
Jan 1, 2023
-25.93 M PLN
Jan 1, 2024
-12.07 M PLN
Jan 1, 2025
-6.33 M PLN
The Pure Biologics EBITDA history
YEAREBITDAYoY
-6.33 MPLN-47.57%
-12.07 MPLN-53.44%
-25.93 MPLN+17.18%
-22.13 MPLN+192.67%
-7.56 MPLN-34.56%
-11.56 MPLN+217.93%
-3.63 MPLN+764.77%
-420,318.80PLN+49.08%
-281,947.84PLN-23.95%
-370,753.50PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pure Biologics Stock analysis

What does Pure Biologics do? Pure Biologics SA, headquartered in Wrocław, Poland, operates in the Health Care sector as a biotechnology company. It focuses on research and development of innovative biological medicines and medical devices for therapeutic and diagnostic applications. The company employs 53 full-time staff and was listed on the stock market on 11 December 2018. Founded in August 2010, it remains based in Wrocław, focusing on biopharmaceutical solutions. Pure Biologics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pure Biologics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Pure Biologics is -6.33 M PLN in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Pure Biologics changed from -12.07 M PLN to -6.33 M PLN, representing a -47.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Pure Biologics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Pure Biologics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Pure Biologics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Pure Biologics